biospectrumasiaApril 25, 2018
Tag: Orexigen , Nalpropion Pharma
Orexigen, a California-based pharmaceutical company focused on development of treatments for obesity announced that it has inked an agreement with Nalpropion Pharmaceuticals to sell virtually all of its assets for $75M in cash.
Nalpropion is a newly formed special purpose entity capitalized by an investor group that includes Pernix Therapeutics. Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market.
The transaction is subject to higher/better offers.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: